Pharmaceutical companies achieved major breakthroughs in 2024

In 2024, several pharmaceutical companies made significant advancements in medical treatments, bringing new hope for various conditions that have seen little change over the years. Eli Lilly received FDA approval in July for Kisunla, a groundbreaking drug for early-stage Alzheimer's disease. This drug is the first of its kind shown to slow cognitive decline. In September, Bristol Myers Squibb launched Cobenfy, the first new schizophrenia drug in 70 years. This treatment uses a novel approach that targets different receptors compared to existing medications. ARS Pharmaceuticals also made headlines with Neffy, a needle-free nasal spray for severe allergic reactions. This innovation is designed to help those who fear needles, and it could be particularly valuable for emergency situations. Cancer treatment saw important developments as well. Iovance Biotherapeutics received accelerated approval for Amtagvi, a T-cell therapy aimed at advanced melanoma. Similarly, Adaptimmune launched Tecelra, an engineered cell therapy for synovial sarcoma, marking a major advancement in cancer therapies. Verona Pharma introduced Ohtuvayre, a new inhaled treatment for chronic obstructive pulmonary disease (COPD). This drug provides a new option for the millions suffering from this respiratory condition. Pfizer also made progress in hemophilia treatment with Hympavzi, which offers a once-weekly injection for better blood clotting control. Additionally, ImmunityBio received approval for Anktiva, a novel treatment for bladder cancer that enhances the immune response. Lastly, Zevra Therapeutics launched Miplyffa, an oral medication for Niemann-Pick disease, type C. This disease causes severe neurological symptoms, and Miplyffa is the first drug approved for treating these symptoms in both adults and children. These innovations show a strong trend towards advancing therapeutic options across various health challenges, emphasizing improved accessibility and effectiveness.